Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

• Status: Unknown status
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT) is still a problem even after donor lymphocyte infusion.

Interferon seemed to augment graft-versus-leukemia (GVL) effect in this part of patients.

the study is to evaluate the safety and efficacy of interferon for the intervention of molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University People's Hospital
• Treatments: Interferon-alpha; Interferons

Criteria

Inclusion Criteria:

• high risk t (8; 21) AML

• molecular relapse after allo-SCT

Exclusion Criteria:

• active graft-versus-host disease

• uncontrolled severe infection

• organ function failure